Study of ATG-022 for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, ATG-022, compared with standard treatments for people with advanced stomach or gastroesophageal junction cancer that has grown after at least two previous treatments. The tumor must have a specific marker called Claudin 18.2.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or spread stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments, including chemotherapy with fluoropyrimidine and platinum.
- Your cancer tests positive for a protein called Claudin 18.2.
- You are able to perform daily activities (ECOG 0 or 1) and have a life expectancy of at least 12 weeks.
- Your blood tests show adequate organ function, and you are willing to provide a tissue sample if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combo (ATG-022 plus pembrolizumab, with or without chemo) for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN 18.2) and is HER2-negative and PD-L1-positive. It may be an option if you have not had certain prior treatments.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This early-phase study tests ATG-022 in adults with advanced or metastatic solid cancers that have progressed on standard treatment, cannot use standard treatment, or have no standard option. It may help by targeting cancer cells differently, and participation includes close monitoring and likely a biopsy.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
This trial tests a new drug called CT0494BCP for advanced stomach cancer that has not responded to previous treatments. The drug targets a protein called CLDN18.2, which is found on many stomach cancer cells, and aims to help your immune system fight the cancer.
This study tests whether giving treatment based on the specific markers of your tumor can better control advanced stomach cancer. The goal is to match the right therapy to each person's cancer.
Hear when a new Advanced Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.